



REFERENCES

- Allahtavakoli, M.; Shabanzadeh, A.P.; Sadr, S.S.; Parviz, M. and Djahanguiri, B. (2006):** Rosiglitazone, a peroxisome proliferator-activated receptor- γ ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. *Clin Exper Pharmacol Physiol.*, 33:1052–1058.
- Alpert, J.S.; Thygesen, K.; Antman, E. and Bassand, J.P. (2000):** "Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction". *J Am Coll Cardiol.*, 36: 959–69.
- Altshuler, D.; Hirschhorn, J. N.; Klannemark, M.; Lindgren, C.M.; Vohl, M.C.; Nemesh, J.; Lane, C. R.; Schaffner, S. F.; Bolk, S.; Brewer, C.; Tuomi, T.; Gaudet, D.; Hudson, T.J.; Daly, M.; Groop, L. and Lander, E.S. (2000):** The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat. Genet.*, 26: 76–80.
- Altunbas, H.; Balci, M.K. and Karayalcin, U. (2003):** No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. *Endocr Res.*, 29: 265-275.
- Andrews, T.C.; Ballantyne, C.M.; Hsia, J.A. and Kramer, J.H. (2001):** Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. *Am J Med.*, 111:185-91.



- Antman, E.M.; Anbe, D.T.; Armstrong, P.W.; Bates, E.R.; Green, L.A.; Hand, M.; Hochman, J.S.; Krumholz, H.M.; Kushner, F.G.; Lamas, G.A.; Mullany, C.J.; Ornato, J.P.; Pearle, D.L.; Sloan, M.A. and Smith, S.C. Jr (2004):** "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)". *J Am Coll Cardiol.*, 44: 671–719.
- Ariane, S.; Michael, G.; Ali, E.; Grit, H.; Alexander, S. and Heimo, E. (2009):** Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. *Cardiovascular research .*, 82 :100.
- Bagby, S.P. (2004):** Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? *J Am Soc Nephrol .*,15:2775–2791.
- Barbagallo, M.; Dominguez, L.J.; Galioto, A.; Ferlisi, A.; Cani, C.; Malfa, L.; Pineo, A.; Busardo, A. and Paolisso, G. (2003):** Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. *Mol Aspects Med.*, 24: 39–52.
- Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J.; Chatterjee, V.K. and O’Rahilly, S. (1999):** Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature.*, 402: 880–883.



- Bax, L.; Algra, A.; Mali, W.P.; Edlinger, M.; Beutler, J.J. van Der Graff, Y. (2008):** Renal function as a risk indicator for cardiovascular events in 3216 patients with manifest arterial disease. *Atherosclerosis* 200: 184.
- Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J.; Hardies, J.; Balas, B.; Gastaldelli, A.; Tio, F.; Pulcini, J.; Berria, R.; Ma, J.Z.; Dwivedi, S.; Havranek, R.; Fincke, C.; DeFronzo, R.; Bannayan, G.A.; Schenker, S. and Cusi, K. (2006):** "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". *N. Engl. J. Med.*, 355: 2297–307.
- Berger, J.P.; Akiyama, T.E. and Meinke, P.T. (2005):** PPARs: therapeutic targets for metabolic disease. *Tre Pharmacol Sci.*, 26: 244-251.
- Bergman, R.N. and Ader, M. (2000):** Free fatty acids and pathogenesis of type 2 diabetes mellitus. *Trends Endocrinol Metab.*, 11: 351-365.
- Bickel, C.; Rupprecht, H.J.; Blankenberg, S. et al., (2002):** Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. *Am J Cardiol.*, 89:12–17.
- Biscetti, F.; Straface, G.; Pitocco, D.; Zaccardi, F.; Ghirlanda, G. and Flex, A. (2009):** Peroxisome proliferator-activated receptors and angiogenesis. *Nutr Met Card Dis.*, 19: 751-759.
- Boden, G.; Sargrad, K.; Homko, C.; Mozzoli, M. and Stein, T.P. (2005):** Effect of a low carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. *Annals of Internal Medicine.*, 142: 403-411.



- Boersma, E.; Maas, A.C.; Deckers, J.W. and Simoons, M.L. (1996):** "Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour." *Lancet.*, 348: 771-5.
- Boersma, E.; Mercado, N. and Poldermans, D. et al., (2003):** acute myocardial infarction. *Lancet.*, 361: 847-58.
- Boie, E.T. (2005):** "Initial evaluation of chest pain". *Emerg. Med. Clin. North Am.*, 23: 937-57.
- Borch-Johnsen, K. (2006):** Colagiuris, Vistisen, Don behalf of the DETECT-2 Collaboration. Is there abimodal distribution of plasma glucose American Diabetes anociation Annual. Scientific Meeting. *Diabetes*, 55 (suppl 1), A19 (Abstract 77).
- Braunwald, E.; Antman, E.M.; Beasley, J.W.; Califf, R.M.; Cheitlin, M.D.; Hochman, J.S.; Jones, R.H.; Kereiakes, D.; Kupersmith, J.; Levin, T.N.; Pepine, C.J.; Schaeffer, J.W.; Smith, E.E. III, Steward, D.E. and Thérroux P. (2002):** "ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)". *J Am Coll Cardiol.*, 40: 1366-74.
- Braunwald, M.D.; ScD, F.R.CP, Douglas P Ziper MD MACC, Peter Libby, MD, et al (2005):** Text book of cardiovascular medicine, 7th edition, by Elsevier Inc. 05:0-8089-2334.
- Brettenthaler, N.; De Geyter, C.; Huber, P.R. and Keller, U. (2004):** Effect of the insulin sensitizier pioglitazone on insulin resistance,



hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.*,89: 3835-40.

Bright, J.J.; Kanakasabai, S.; Chearwae, W. and Chakraborty, S. (2008): ppar regulation of inflammatory signaling in CNS diseases. *PPAR Res.*,12: 1565-75.

Brown, D.J. and Jorge, P. (2007): Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. *Circulation.*, 115:518-533.

Calvo, C.; Ramon, C.; Covelo, D.M.; Jose, E. (2003): Hypertension and Vascular Risk Unit, *American Journal of Hypertension* Volume 16, Issue 5, Supplement 1, Page A44-51.

Cangiano, J.L.; Carmen, R.S. and Mauuel, M.M. (1978): Effect of antihypertensive treatment on systolic blood pressure and rennin in hypertensive rats.

Canto, J.G.; Shlipak, M.G.; Rogers, W.J.; Malmgren, J.A.; Frederick, P.D.; Lambrew, C.T.; Ornato, J.P.; Barron, H.V. and Kiefe, C.I.. (2000): "Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain". *JAMA.*, 283: 3223–9.

Castro, E.; Rizzi, R.R.; Rascado, S.; Nagassaki, L.M.; Bendhack and J.E. (2004): Tanus-Santos, Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms, *Eur. J. Pharmacol.*, 498: 189–194.

Chen, Z.; Ishibashi, S.; Perrey, S.; Osuga, J.; Gotoda, T.; Kitamine, T.; Tamura, Y.; Okazaki, H.; Yahagi, N.; Lizuka, Y.; Shionoiri, F.;



- Ohashi, K.; Harada, K.; Shimano, H.; Nagai, R. and Yamada, N. (2001):** Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. *Arterioscler Thromb Vasc Biol.*, 21:372-377.
- Chitrang, J.; Trivedi, R.; Balaraman, Jayesh, B. and Sunil, B. (2006):** Effect of Atorvastatin Treatment on Isoproterenol-Induced Myocardial Infarction in Rats. *Pharmacology*, 77:25-32.
- Chiu, K.C.; Chu, A.; Go, V.L. and Saad, M.F. (2004):** Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *American Journal of Clinical Nutrition*, 79:820-825.
- Colca, J.R.; McDonald, W.G.; Waldon, D.J.; Leone, J.W.; Lull, J.M.; Bannow, C.A.; Lund, E.T. and Mathews, W.R. (2004):** "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". *Am. J. Physiol. Endocrinol. Metab.*, 286: E252–60.
- Colhoun, H.M.; Betteridge, D.J.; Durrington, P.N.; Hitma, G.A.; Neil, H.A.; Livingstone, S.J.; Thomason, M.J.; Mackness, M.I.; Charlton-Menys, V. and Fuller, J.H. (2004):** CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet*, 364: 685-96.
- Collins, R.; Armitage, J.; Parish, S.; Sleight, P. and Peto R. (2003):** MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*, 361: 2005-2016.



- Dahl-Jorgensen, K. (1999):** Modern insulin therapy in children and adolescents. *Acta Paediatr Suppl.*,88:25-30.
- Dahlof, B.;Sever, P.S.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; et al. (2003):** Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet.*,361:1149-58.
- Dargie, H.J. (2001):** "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the capricorn randomised trial". *Lancet.*, 357: 1385–90.
- Davis, T.M.; Fortun, P.; Mulder, J.; Davis, W.A. and Bruce, D.G. (2004):** "Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study". *Diabetologia.*, 47: 395–9.
- DeFronzo, R.; Tobin, J. and Andres, R. (1979):** Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am. J. Physiol.*, 297: E214-23.
- Deng, L.J. et al., (2005):** Effect of gemfibrozil on the pharmacokinetics of pioglitazone. *Eur J Clin Pharmacol.*,61: 831-836.
- Desvergne, B. and Wahli, W. (1999):** Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr Rev.*, 20: 649-688.



- Diamant, M. and Heine, R.J. (2003): Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. *Drugs.*, 63 :1373 – 1405.**
- Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.A. et al., (2005):** Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised controlled trial. *Lancet.*, 366: 1279-1289.
- Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G. and Wahli, W. (1992):** Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell.*, 68: 879-887.
- Efendic, S.; Karlander, S. and Vranic, M. (1988):** Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity. *J Clin Invest.*, 81: 1953-1961.
- Efthymiou, C.A.; Mocanu, M.M. and Yellon, D.M. (2005):** Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. *J. Cardiovasc. Pharmacol.*, 45:247-252.
- Eisenman, A. (2006):** "Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand?". *Expert Rev Cardiovasc Ther.*, 4: 509–14.
- Erdmann, E.; Dormandy, J.A.; Charbonnel, B.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M. (2007):** The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2



diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol.,49: 1772-80.

Fishbein, M.C. (1990): "Reperfusion injury". Clin Cardiol .,13: 213–7.

Flores-Riveros, J.R. (1993): Insulin- down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover. Proc. Natl. Acad. Sci. USA., 90:512.516.

Fossati, P. (1982): Enzymatic determination of seum triglycerides. Principle Clin. Chem., 28, 2077.

Francis, S. (2001): Diabetic cardiomyopathy: fact or fiction? Heart., 85:247-248.

Freeman, D.J.; Norrie, J.; Sattar, N.; Nely, R.D.; Cobbe, S.M.; Ford, I.; Isles, C.; Lorimer, A.R.; Macfarlane, P.W.; Mckillop, J.H.; Packard, C.J.; Shepherd, A. and Gaw, A. (2001): Pravastatin and the development of diabetes mellitusL evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Cir- culation., 103: 357-362.

Friedewald, W.T. et al., (1972): Clin. Chem. 18:499-512.

Fukuchi, S. (2004): Role of Fatty Acid Composition in the Development of Metabolic Disordersin Sucrose-Induced Obese Rats Experimental Biology and Medicine., 229:486-493.

Furchgott, R.F. and Bhadrakon, S. (1953): Reaction of strips of Rabbit aorta to epinephrin Isoropy arterenol, sodium nitrate and other drugs.J. Pharmacol. Exp. Thes. 18 : 129 – 143.



- Gedulin, B.R.; Nikoulina, S.E.; Smith, P.A.; Gedulin, G.; Nielsen, L.L. Baron, A.D.; Parkes, D. and Young, A.A. (2005):** Exenatide (exendin-4) improves insulin sensitivity and β -cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. *Endocrinology.*, 146:2069–2076.
- Gerard, D.; Angelo, Ahmed, A.; Elmarakby, David, M. and David, W. (2005):** Fructose Feeding Increases Insulin Resistance but Not Blood Pressure in Sprague-Dawley Rats. *Hypertension.*, 46:806.
- Ghirlanda, G.; Oradei, A.; Manto, A.; Lippa, S.; Uccioli, L.; Caputo, S.; Greco, A. and Littarru, G. (1993):** "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". *J Clin Pharmacol.*, 33: 226–9.
- Gillies, P.S. and Dunn, C.J. (2000):** "Pioglitazone". *Drugs.*, 60: 333–43.
- Gillum, R.F.; Fortmann, S.P.; Prineas, R.J. and Kottke, T.E. (1984):** International diagnostic criteria for acute myocardial infarction and acute stroke. *Am Heart J.*, 108:150-8.
- Goke, B.; Lubben, G. and Bates, P.C. (2004):** Coefficient of beta- cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. *Exp clin Endocrinol Diab etes.*, 112: 115-17.
- Goldberg, R.B.; Kendall, D.M.; Deeg, M.A.; Buse, J.B.; Zagar, A.J.; Pinaire, J.A.; Tan, M.L.L.; Khan, M.A.; Perez, A.T. and Jacober, S.J. (2005):** A comparions of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care.*, 28:1547-1554.



GPnotebook, Myocardial infarction: diagnosis and investigations- retrieved November 27, 2006.

Haffner, S.M.; Lehto, S.; Ronnemaa, T.; Pyorala, K. and Laakso, M. (1998): Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339-234.

Harinantenaina, L. (2006): Momordica charactia constituents and antidiabetic screening of the isolated major compounds. Chemical & Pharmaceutical Bulletin (Tokyo)., 54:1017-1021.

Hawang, J.; Kleinhenz, D.J.; Lasseque, m B.; Griendling, K.K.; Dikalov, S. and Hart, C.M. (2005): Peroxisome proliferators- activated receptor- gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol., 288: C899-c905.

Hochman, J.S.; Choo, H. and Hirsh, L.E. (1987): Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation, 20: 313 – 323.

Hochman, J.S.; Sleeper, L.A.; Webb, J.G.; Sanborn, T.A.; White, H.D.; Talley, J.D.; Buller, C.E.; Jacobs, A.K.; Slater, J.N.; Col, J.; McKinlay, S.M. and LeJemtel, T.H. (1999). "Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock". N. Engl. J. Med., 341: 625–34.



- Hsueh, W.A. and Law, R.E. (1998):** Cardiovascular risk continuum: implications of insulin resistance and diabetes. *Am. J. Med.*, 105: 4S-14S.
- Issemann, I. and Green, S. (1990):** Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature.*, 347:645-650.
- Ito, H.; Nakano, A.; Kinoshita, M. and Matsumori, A. (2003):** Pioglitazone, a peroxisome proliferators-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. *Lab. Invest.*, 83:1715-1721.
- Jaakkola, T.; et al., (2006):** Effect of rifampicin on the pharmacokinetics of pioglitazone. *Clin. Pharmacol. Brit. Jour.*, 61:1 70-78.
- Jeff, Unger, (2008):** *Emergency Medicen. Retrieved on 2008-01-13.*
- Jiang, C.; Ting, A.T. and Seed, B.(1998):** PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature.*,391: 82–86.
- Josephson, Mark E. (2002):** Clinical Cardiac Electrophysiology: Techniques and Interpretations. Lippincott Williams & Wilkins. ISBN 0683306936.
- Jpenberg, A.I.; Jeannin, E.; Wahli, W. and Desvergne, B. (1997):** Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. *J. Biol. Chem.*,272: 20108–20117.



- Kane, G.C. and Lipsky, J.J. (2000).** "Drug-grapefruit juice interactions". Mayo Clin. Proc., 75: 933–42.
- Kashani, A.; Phillips, C.O.; Foody, J.M.; et al. (2006):** Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation., 114:2788-2797.
- Kawamoto, A.; Gwon, H.C.; Iwaguro, H.; et al., (2001):** Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation., 103:634-637.
- Kayikcioglu, M.; Payzin, S.; Yavuzgil, O.; Kultursay, H.; Can, L.H. and Soydan, I. (2003).** Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J., 24:1999-2005.
- Keating, G. and Plosker, G. (2004):** "Eplerenone: a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction". Drugs., 64: 2689–707.
- Kersten, J.; Toller, W.; Tessmer, J.; Pagel, P. and Warltier, D. (2001):** Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am. J. Physiol., 281:H2097–H2104
- Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. (2003):** Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J. Hypertens., 21:379-86.
- Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A. and Nathan, D.M. (2002):** Reduction



in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*., 346: 393-403.

Koska, J.; Ortega, E.; Bunt, J.C.; Gasser, A.; Impson, J.; Hanson, R.L.; Forbes, J.; de Courten, B. and Krakoff, J. (2009): The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. *Diabetologia*.,52:385-93.

Kosuge, M.; Kimura, K.; Ishikawa, T.; et al. (2006): "Differences between men and women in terms of clinical features of ST-segment elevation acute myocardial infarction". *Circulation Journal*.,70: 222–226.

Kota, B.P.; Huang, T.H. and Roufogalis, B.D. (2005): An overview on biological mechanisms of PPARs. *Pharmacol. Res.*, 51:85–94.

Krijnen, P.A.; Nijmeijer, R.; Meijer, C.J.; Visser, C.A.; Hack, C.E. and Niessen, H.W. (2002). "Apoptosis in myocardial ischaemia and infarction". *J. Clin. Pathol.*, 55: 801–11.

Landmesser, U.; Enberding, N.; Bahlmann, F.; Schaefer, A.; et al., (2004): Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase Circulation., 110:1933-1939.

Langendorff (1895): *Pflugers Arc. Ges. Physiol.*, 190, 280. quoted from pharmacological experiments on isolated preparations, 1970 by the staff of department of pharmacology, University of Edinburgh. ESS. Livingstone, Edinburgh & Lond.



- Law, M.R.; Wald, N.J. and Rudnicka, A.R. (2003):** "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis". *BMJ.*, 326: 1423.
- Leaf, A.; Albert, C.; Josephson, M.; Steinhaus, D.; Kluger, J.; Kang, J.; Cox, B.; Zhang, H. and Schoenfeld, D. (2005).** "Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake". *Circulation.*, 112: 2762–8.
- Lehmann, J.M.; Moore, L.B.; Smith-Oliver, T.A.; Wilkison, W.O.; Willson, T.M. and Kliewer, S.A. (1995):** An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR- γ). *J. Biol. Chem.*, 270, 12953–12956.
- Lincoff, A.M.; Wolski, K.; Nicholls, S.J. and Nissen, S.E. (2007):** Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA.*, 298:1180-8.
- Little, R.A.; Frayn, K.N.; Randall, P.E. et al., (1986):** "Plasma catecholamines in the acute phase of the response to myocardial infarction". *Arch. Emerg. Med.*, 3 : 20–7.
- Liu, Y. and Anne Miller. R. (2005):** Ligands to peroxisome proliferator-activated receptors as therapeutic options for metabolic syndrome. *Drug Discovery Today: Therapeutic Strategies.*, 2: 165-169.
- Lowe G.(2001):** The relationship between infection, inflammation, and cardiovascular disease: an overview. *Ann Periodontol.*, 6: 1–8.



- Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T. and Matsuzawa, Y. (2002):** Diet-induced insulin resistance in mice lacking adipo nectin/ACRP30. *Nat. Med.*, 8: 731-737.
- Majithiya, J.B.; Paramar, A.N. and Balaraman, R. (2005):** Pioglitazone, aPPAR-gamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. *Cardiovasc. Res.*, 66:150-161.
- Marcus, G.M.; Cohen, J.; Varosy, P.D.; et al., (2007):** "The utility of gestures in patients with chest discomfort". *Am. J. Med.*, 120 : 83–9.
- Matsumoto, T.; Noguchi, E.; Kobayashi, T. and Kamata, K. (2007):** Mechanisms underluying the chronic pioglitazone treatment-induced improvement in the imparied endothelium-dependent relaxation seen in aortas from diabetic rats. *Free Radic. Biol. Med.*, 42:993-1007.
- Matthews,D.R.;Hosker,J.P;Rudenski,A.S.;Naylor,B.A;Treacher,D.f;Turner,R.C.(1985):**Homeostasis model assessment :insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man.*Diabetaologia*;28:412-419.
- McCord, J.; Jneid, H.; Hollander, J.E.; et al., (2008):** "Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute



Cardiac Care Committee of the Council on Clinical Cardiology".
Circulation., 117: 1897–907.

McCrindle, B.W.; Ose, L. and Marais, A.D. (2003): "Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial". J. Pediatr., 143: 74–80.

McGarry, J. (2002): Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes., 51:7-18.

McSweeney, J.C.; Cody, M.; O'Sullivan, P.; Elbersson, K.; Moser, D.K. and Garvin, B.J. (2003): Women's early warning symptoms of acute myocardial infarction. Circulation., 108: 2619-23.

Meine, T.J.; Roe, M.T.; Chen, A.Y. et al., (2005). "Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative". Am. Heart J., 149: 1043–9.

Mensah, K.; Mocanu, M.M. and Yellon, D.M. (2005): Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog detected on chromosome ten? J. Am. Coll. Cardiol., 45:1287-1291.

Michael J.; Shin, E.K.; Han, S.H.; Lee, Y. et al., (2010): Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. J Am Coll Cardiol 55:1209-1216.



- Michalik, L. and Wahli, W. (2006):** Involvement of PPAR nuclear receptors in tissue injury and wound repair. *J. Clin. Invest.*, 116: 598-606.
- Mohammadi, H.; Hassar, M.; Qarbal, F.; Hilal, L. et al., (2009):** Glycaemic Control, HbA1c, and Lipid Profile in Children with Type 1 Diabetes Mellitus. *European Journal of Scientific Research* ISSN 1450-216X Vol.29 No.2 pp.289-294.
- Naito, Y. and Yoshikawa, T. (2004):** Thiazolidinediones: A new class of drugs for the therapy of ischemia-reperfusion injury. *Drugs Today.*, 40: 423 .
- Neil, H.A.; DeMicco, D.A.; Luo, D. et al., (2006):** "Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)". *Diabetes Care.*,29: 2378–84.
- Niemi, M.; Backman, J.T.; Neuvonen, M.; et al., (2003):** Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. *Diabetologia* .,46:347–51.
- Niemi, M.; Kajosaari, L.I.; Neuvonen, M. et al., (2004):** The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. *Br. J. Clin. Pharmacol.*,57:441–7.
- Nirmala, C. and Puvanakrishnan, R. (1994):** Isoproterenol Induced myocardial infarction in rats: functional and biochemical alteration. *Med. Sci. Res.*,22:575-7.



- Nissen, S.; Nicholls, S.; Sipahi, I.; Libby, P.; Raichlen, J.; Ballantyne, C.; Davignon, J.; Erbel, R.; Fruchart, J.; Tardif, J.; Schoenhagen, P.; Crowe, T.; Cain, V.; Wolski, K.; Goormastic, M. and Tuzcu, E. (2006):** "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". JAMA.,295: 1556–65.
- Nissen, S.E.; Nicholls, S.J. and Wolski, K. (2008):** "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes". JAMA.,299: 1561.
- Noma, A.; Okabe, H.; Nakayama, K.; Ueno, Y.; Shinohara, H. (1979):** Improved method for simultaneous determination of cholesterol in high- and low-density lipoproteins. Clin. Chem.,25:1480-1481.
- Nomura, H.; Yamawaki, Hi.; Mukohda, M.; Okada, M. and Hara, Y. (2008):** Mechanisms underlying Pioglitazone-Mediated Relaxation in Isolated Blood Vessel. J. Pharmacol. Sci., 108:258-265.
- Okuno, A.; Tamemoto, H. and Tobe, K. (1998):** Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest., 101:1354-1361.
- Paddock, M.L.; Wiley, S.E.; Axelrod, H.L.; Cohen, A.E.; Roy, M.; Abresch, E.C.; Capraro, D.; Murphy, A.N.; Nechushtai, R.; Dixon, J.E. and Jennings, P.A. (2007):** "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proc. Natl. Acad. Sci. U.S.A., 104: 14342–7.
- Paget, G. and Barnes, J. M. (1964):** Evaluation of drug activities, pharmacometric; vol. 1, Academic Press, London- New York.



- Paolisso, G.; Barbagallo, M.; Petrella, G.; Ragno, E.; Barbieri, M; Giordano, M. and Varricchio, M. (2000):** Effect of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. *Atherosclerosis*, 150: 121-127.
- Parra, H.J.; Arveiler, D.; Evans, A.E.; Cambou, J.P.; Amouyel, P.; Bingham, A. et al. (1992):** A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. *Arterioscler. Thromb.*, 12:701-7.
- Paul, S. (2002):** Exercise-induced transcription of the muscle Glucose transporter (GLUT4) Gene". *Biochemical and biophysical research communications*, 292: 409-414.
- Peters, R.J.; Mehta, S.R.; Fox, K.A.; Zhao, F.; Lewis, B.S.; Kopecky, S.L.; Diaz, R.; Commerford, P.J.; Valentin, V. and Yusuf, S. (2003):** "Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study". *Circulation*, 108: 1682–7.
- Pfeffer, M.A.; Braunwald, E.; Moye, L.A.; Basta, L.; Brown, E.J.Jr, Cuddy, T.E.; Davis, B.R.; Geltman, E.M.; Goldman, S.; Flaker, G.C. et al., (1992):** "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators". *N. Engl. J. Med.*, 327: 669–77.
- Pfutzner, A.; Hohbberg, C.; Lubben, G.; Pahler, S.; Pfutzner, A.H.; Kann, P. and Forst, T. (2005):** Pioneer study: PPARgamma



activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. *Horm Metab. Res.*, 37:510-515.

Pham, T.; Cornea, A.; Blick, K.E.; Jenkins, A. and Scofield, R.M.I.D. (2007): Oral Glucosamine in Doses Used to Treat Osteoarthritis Worsens Insulin Resistance. *The American Journal of the Medical Sciences.*, 333: 333-339.

Ramachandran, A.; Snehalatha, C.; Mary, S.; Selvam, S.; Kumar, C.K.; Seeli, A.C. and Shetty, A.S. (2009): Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). *Diabetologia.*, 52:1019-26.

Rangwala, S.M. and Lazar, M.A. (2004): Peroxisome proliferator-activated receptor gamma in diabetes and metabolism, *Trends Pharmacol. Sci.*, 25: 331–336.

Rangwala, S.M.; Rhoades, B.; Shapiro, J.S.; Rich, A.S.; Kim, J.K. Shulman, G.I.; Kaestner, K.H. and Lazar, M.A. (2003): Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. *Dev. Cell.*, 5: 657–563.

Ray, K.K. and Cannon, C.P. (2005): "The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes". *J. Am. Coll. Cardiol.*, 46: 1425–33.

Ricote, M.; Huang, J.; Fajas, L.; Li, A.; Welch, J.; Najib, J.; Witztum, J.L.; Auwerx, J.; Palinski, W. and Glass C.K. (1998): Expression



of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. *Proc. Natl. Acad. Sci. USA.*, 95: 7614–7619.

Robinson, E. and Grieve, D.J. (2009): Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. *Pharmacol Ther.*, 122: 246-263.

Rosanio, S.; Ye, Y.; Atar, S.; Rahman, A.M.; Freeberg, S.Y.; Huang, M.H.; Uretsky, B.F. and Birnbaum, Y. (2006): Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. *Cardiovasc Drugs Ther.*, 20:27-36.

Rosenstock, J.; Einhorn, D.; Hershon, K.; et al., (2002): Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. *Int J Clin Pract.*, 56:251–7.

Rossi, S. (2006): Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook;. ISBN 0-9757919-2-3.

Roy, S. (2006): Myocardial infarction. Retrieved November 28.

Russo, M.W.; Galanko, J.A.; Shrestha, R.; Fried, M.W. and Atkins, P. W. (2004): Liver transplantation for acute liver failure from drug induced liver injury in the United States. *Liver Transpl.*, 10: 1018–1023.

Sabatine, M.S.; Morrow, D.A.; Montalescot, G.; Dellborg, M.; Leiva-Pons, J.L.; Keltai, M.; Murphy, S.A.; McCabe, C.H.; Gibson,



- C.M.; Cannon, C.P.; Antman, E.M. and Braunwald, E. (2005):** "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial". *Circulation.*, 112: 3846–54.
- Saikku, P.; Leinonen, M.; Tenkanen, L.; Linnanmaki, E.; Ekman, M.R.; Manninen, V.; Manttari, M.; Frick, M.H. and Huttunen, J.K. (1992):** Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. *Ann. Intern. Med.*, 116:273-8.
- Schaeffner, E.S.; Kurth, T.; Curhan, G.C.; et al., (2003):** Cholesterol and the risk of renal dysfunction in apparently healthy men. *J. Am. Soc. Nephrol.*, 14:2084–2091.
- Shepherd, J.; Cobbe, S.M.; Ford, I.; et al., (1995):** for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N. Engl. J. Med.*, 333:1301–1307.
- Shimazu, T.; Inoue, I.; Araki, N.; Asano, Y.; and Sawada, M.(2005):** A Peroxisome Proliferator-Activated Receptor- γ Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia. *Stroke.*, 36:353.
- Shinmura, K.; Xuan, Y.R.; Tang, X.L.; Kodani, E.; Han, H.; Zha, Y. and Bolli, R. (2002):** Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. *Circ. RES.*, 90: 602-608.



- Shi-ying, DI.N.G.; Zhu-fang, S.H.E.N.; Yue-teng, C.H.E.N.; Su-juan, S.U.N.; Quan Liu and Ming- zhi, X.I.E. (2005):** Pioglitazone can ameliorate insulin resistance in low- dose streptozotocin and high sucrose- fat diet induced obese rates. *Acta pharmacologica sinica.*, 26:5- 580.
- Siedel, J.H.; Schlumberger, S.; Klose, J.; Washlefeld, A.W. (1991):** quoted from Boehringer Mannheim GMBH Diagnostic Manual. *J. Clin. Chem. Clin. Bioch.*, 19:838.
- Skoufis, E. and McGhie, A.I. (1998):** "Radionuclide techniques for the assessment of myocardial viability". *Tex. Heart Inst. J.*, 25: 272–9.
- Solinas Giovanni et al., (2007):** JNK1 in Hematopoietically Derived Ceel Contributes to Diet-Induced inflammation and Insulin Resistance without Affecting Obesity". *Cell Metabolism.*, 6:386-397.
- Somers, M.P.; Brady, W.J.; Perron, A.D. and Mattu, A. (2002).** "The prominent [sic] T wave: electrocardiographic differential diagnosis". *Am. J. Emerg. Med.*, 20: 243–51.
- Soutoglou, E.; Viollet, B.; Vaxillaire, M.; Yaniv, M.; Pontoglio, M. and Talianidis, I. (2001):** Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. *EMBO J.*, 20: 1984–1992.
- Spiegelman, B.M. (1998):** PPAR- γ : Adipogenic regulator and thiazolidinedione receptor. *Diabetes.*, 47: 507-517.
- Steiner, G. (2007).** "Atherosclerosis in type 2 diabetes: a role for fibrate therapy?". *Diab. Vasc. Dis. Res.*, 4: 368–74.



- Stumvoll, M. and Haring, H.U. (2002):** Glitazones: clinical effects and molecular mechanisms. *Ann. Med.*, 34:217–224.
- Suzuki, M.; Kakuta, H.; Takahashi, A.; Shimano, H.; Tada-Lida, K.; Yokoo, T.; Kihara, R. and Yamada, N. (2004):** Effects of Atorvastatin on Glucose Metabolisms and Insulin Resistance in KK/Ay Mice. *Journal of Atherosclerosis and Thrombosis* Vol., 12: 2-17.
- Szasz, J.F.; Harricane, M.C.; Nargeot, J. and Richard, S. (1976):** Measurement of CPK- MB serum level. *J. Clin. Invest.*, 33 : 185 – 193.
- Tawfik, M.; Maivel, H.; Ghattas, B. et al., (2010):** Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. *Eur. Rev. Med. Pharmacol. Sci.*, 14: 499-506.
- The world health report (2004)** Changing history. World Health Organization. 120-124.
- Thornburn, A.W.; Storlein, L.H.; Jenkins, A.B.; Khouri, S. and Kraegen, E.W. (1989):** Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. *Am. J. Clin. Nutr.*, 49: 1155-63.
- Trochu, J.N.; Bouhour, J.B.; Kaley, G.; et al., (2000):** Role of endothelium- derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. *Circ. Res.*, 87: 1118-1117.
- Tsukamoto, H.; Hishinuma, T.; Suzuki, N.; Fayama, R.; Hiratsuka, M.; Yoshihisa, T.; Mizugaki, M. and Goto, J. (2004):**



Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferators-activated receptor gamma-independent manner. Prostaglandins Other Lipid Mediat., 73: 191-213.

Wakino, S.; Hayashi, K.; Tatematsu, S.; Hasegawa, K.; Takamatsu, I.; Kanda, T.; Homma, K.; Yoshioka, K.; Sugano, N. and Saruta, T. (2005): Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res., 28: 255-62.

Wallace, T.; Levy, J. and Matthews, D. (2004): Use and abuse of HOMA modeling. Diabetes care., 27: 1487-95.

Williams, B.; Poulter, N.R.; Brown, M.J. et al (2004): British Hypertension Society guidelines for hypertension management (BHS-IV): summary. BMJ., 328:634-40.

Williams, D. and Feely, J. (2002). "Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors". Clin. Pharmacokinet., 41: 343–70.

Willson, T.; Brown, P.J.; Sternbach, D.D. and Henke, B.R. (2000): The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 43: 527–550.

Wilson, P.W.; D'Agostino, R.B.; Levy, D.; Belanger, AM, Silbershatz H, Kannel WB. (1998):"Prediction of coronary heart disease using risk factor categories". Circulation., 97: 1837-47.

Xiao, C.Y.; Hara, A.; Yuhki, K.; Fujino, T.; Ma, H.; Okada, Y.; Takahata, O.; Yamada, T.; Murata, T.; Narumiya, S. and



- Ushikubi, F. (2001):** Roles of prostaglandin I₂ and thromboxane A₂ in cardiac ischemia- reperfusion injury: a study using mice lacking either respective receptors. *Circulation.*, 104:2210-2215.
- Ye, Y.; Lin, Y.; Atar, S. and Birnbaum, Y. (2006):** Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. *Am. J.*, 114:929-935.
- Yokoyama, J.; Sutoh, N.; Higuma, T.; Horiuchi, D.; Katoh, C.; Yokota, T.; Echizen, T.; Sasaki, S.; Hanada, H.; Osanai, T. and Okumura, K. (2007):** Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. *Heart Vessels.*, 22: 146-51.
- Yoshino, G.; Hirano, T. and Kuzumi, T. (1996):** Dyslipidemia in diabetes mellitus. *Diabetes Res. Clin. Pract.*, 1 –14.
- Yue, T.L.; Bao, W.; Gu, J.L.; Cui, J.; Tao, L.; Ma, X.L.; Ohlstein, E.H. and Jucker, B.M. (2005):** Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. *Diabetes.*, 54:554-562.